<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of this study was to test whether vascular reactivity is modified by improving metabolic control and peripheral <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: In a randomized, double-blind design, we assigned 74 type 2 diabetic patients to <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (8 mg/day), <z:chebi fb="0" ids="6801">metformin</z:chebi> (1,500 mg/day), or placebo treatment for 16 weeks and measured insulin sensitivity (euglycemic insulin clamp), ambulatory blood pressure, and forearm blood flow response to 1) intra-arterial <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> (<z:chebi fb="0" ids="15355">ACh</z:chebi>), 2) intra-arterial <z:chebi fb="0" ids="7596">nitroprusside</z:chebi>, 3) the clamp, and 4) blockade of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) synthase </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Compared with 25 nondiabetic subjects, patients had reduced insulin sensitivity (30 +/- 1 vs. 41 +/- 3 micromol </plain></SENT>
<SENT sid="3" pm="."><plain>min(-1). kg fat-free mass(-1); P &lt; 0.001) and reduced maximal response to <z:chebi fb="0" ids="15355">ACh</z:chebi> (586 +/- 42 vs. 883 +/- 81%; P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Relative to placebo, 16 weeks of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> similarly reduced fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (-2.3 +/- 0.5 and -2.3 +/- 0.5 mmol/l) and HbA(1c) (-1.2 +/- 0.3 and -1.6 +/- 0.3%) </plain></SENT>
<SENT sid="5" pm="."><plain>Insulin sensitivity increased with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (+6 +/- 3 micromol </plain></SENT>
<SENT sid="6" pm="."><plain>min(-1). kg fat-free mass(-1); P &lt; 0.01) but not with <z:chebi fb="0" ids="6801">metformin</z:chebi> or placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Ambulatory diastolic blood pressure fell consistently (-2 +/- 1 mmHg; P &lt; 0.05) only in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="7596">Nitroprusside</z:chebi> dose response, clamp-induced vasodilatation, and NO blockade were not affected by either treatment </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, the slope of the <z:chebi fb="0" ids="15355">ACh</z:chebi> dose response improved with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (+40% versus baseline, P &lt; 0.05, +70% versus placebo, P &lt; 0.005) but did not change with either <z:chebi fb="0" ids="6801">metformin</z:chebi> or placebo </plain></SENT>
<SENT sid="10" pm="."><plain>This improvement in endothelium-dependent vasodilatation was accompanied by decrements in circulating levels of free fatty acids and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: At equivalent glycemic control, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, but not <z:chebi fb="0" ids="6801">metformin</z:chebi>, improves endothelium dependent vasodilatation and insulin sensitivity in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>